TCTC Holdings LLC Has $74,000 Stock Position in GSK plc (NYSE:GSK)

TCTC Holdings LLC grew its holdings in shares of GSK plc (NYSE:GSK) by 30.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 2,178 shares of the pharmaceutical company’s stock after acquiring an additional 510 shares during the period. TCTC Holdings LLC’s holdings in GSK were worth $74,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. FMR LLC grew its holdings in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC grew its holdings in shares of GSK by 14.3% during the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after buying an additional 51,378 shares during the last quarter. Cerity Partners LLC grew its holdings in shares of GSK by 61.8% during the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after buying an additional 165,556 shares during the last quarter. Finally, Natixis Advisors LLC grew its holdings in shares of GSK by 20.0% during the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after buying an additional 83,433 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on GSK shares. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Performance

Shares of GSK stock opened at $40.30 on Tuesday. The firm has a market cap of $83.53 billion, a price-to-earnings ratio of 25.35, a P/E/G ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93. The firm’s 50-day simple moving average is $36.18 and its two-hundred day simple moving average is $36.99.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, equities analysts forecast that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a $0.3932 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 3.90%. GSK’s payout ratio is currently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.